% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nelde:284802,
      author       = {A. Nelde and H. Schuster and J. Heitmann$^*$ and J. Bauer
                      and Y. Maringer and M. Zwick and J.-P. Volkmer and J. Y.
                      Chen and A. M. P. Stanger and A. Lehmann and B. Appiah and
                      M. Märklin$^*$ and E. Rücker-Braun and H. Salih$^*$ and M.
                      Roerden and S. M. Schroeder and M.-F. Häring and A.
                      Schlosser and J. Schetelig and M. Schmitz$^*$ and M.
                      Börries$^*$ and N. Köhler and C. Lengerke$^*$ and R.
                      Majeti and I. L. Weissman and H.-G. Rammensee$^*$ and J.
                      Walz$^*$},
      title        = {{I}mmune {S}urveillance of {A}cute {M}yeloid {L}eukemia
                      {I}s {M}ediated by {HLA}-{P}resented {A}ntigens on
                      {L}eukemia {P}rogenitor {C}ells.},
      journal      = {Blood cancer discovery},
      volume       = {4},
      number       = {6},
      issn         = {2643-3230},
      address      = {Philadelphia, PA},
      publisher    = {American Association for Cancer Research},
      reportid     = {DKFZ-2023-02105},
      pages        = {468-489},
      year         = {2023},
      note         = {2023 Nov 1;4(6):468-489},
      abstract     = {Therapy-resistant leukemia stem and progenitor cells (LSC)
                      are a main cause of acute myeloid leukemia (AML) relapse.
                      LSC-targeting therapies may thus improve outcome of patients
                      with AML. Here we demonstrate that LSCs present
                      HLA-restricted antigens that induce T-cell responses
                      allowing for immune surveillance of AML. Using a mass
                      spectrometry-based immunopeptidomics approach, we
                      characterized the antigenic landscape of patient LSCs and
                      identified AML- and AML/LSC-associated HLA-presented
                      antigens absent from normal tissues comprising nonmutated
                      peptides, cryptic neoepitopes, and neoepitopes of common AML
                      driver mutations of NPM1 and IDH2. Functional relevance of
                      shared AML/LSC antigens is illustrated by presence of their
                      cognizant memory T cells in patients. Antigen-specific
                      T-cell recognition and HLA class II immunopeptidome
                      diversity correlated with clinical outcome. Together, these
                      antigens shared among AML and LSCs represent prime targets
                      for T cell-based therapies with potential of eliminating
                      residual LSCs in patients with AML.The elimination of
                      therapy-resistant leukemia stem and progenitor cells (LSC)
                      remains a major challenge in the treatment of AML. This
                      study identifies and functionally validates LSC-associated
                      HLA class I and HLA class II-presented antigens, paving the
                      way to the development of LSC-directed T cell-based
                      immunotherapeutic approaches for patients with AML. See
                      related commentary by Ritz, p. 437 .},
      cin          = {TU01 / DD01 / FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331 / I:(DE-He78)DD01-20160331 /
                      I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37847741},
      doi          = {10.1158/2643-3230.BCD-23-0020},
      url          = {https://inrepo02.dkfz.de/record/284802},
}